久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

Aldagen是一家開發成體干細胞藥物的生物技術公司

ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
We are a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We are currently conducting clinical trials of the following four product candidates:

- ALD-101 to improve umbilical cord transplants used treat inherited metabolic diseases in pediatric patients;
- ALD-151 to improve umbilical cord blood transplants used for the treatment of leukemia;
- ALD-301 to treat critical limb ischemia; and
- ALD-201 to treat ischemic heart failure.

Our product candidates consist of specific populations of adult stem cells that we isolate using our proprietary technology platform. This platform yields stem cell populations that express high levels of an enzyme known as aldehyde dehydrogenase (ALDH). These cell populations, which we refer to as "ALDH-bright" or "ALDHbr" cell populations, exhibit a variety of activities that we believe may promote the regeneration of multiple types of cells and tissues, and that may therefore have a variety of therapeutic uses.

We manufacture all of our product candidates at a facility located at our corporate headquarters in Durham, North Carolina. This facility is operated in compliance with the current good manufacturing practices (cGMP) and current good tissue practices (cGTP) standards required by the U.S. Food and Drug Administration.